BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
May 31, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

RG1068 regulatory update

Repligen said FDA and the European Medicines Agency (EMA) agreed to a re-read of MRI images from the company's Phase III trial of RG1068 based on "numerous deficiencies" with the analysis conducted by the CRO overseeing the original analysis....

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >